Neuropace Inc (NPCE)

Currency in USD
15.05
+0.55(+3.79%)
Closed·
15.51+0.46(+3.06%)
·

NPCE Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
-0.11 / -0.20
Revenue / Forecast
27.40M / 24.31M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/-0.184--/24.39M----Free Sign Up
09/2025-0.11/-0.227.4M/24.31M+45%+12.71%Free Sign Up
06/2025-0.26/-0.2223.5M/23.09M-18.18%+1.78%Free Sign Up
03/2025-0.21/-0.2422.52M/21.85M+12.5%+3.07%Free Sign Up
12/2024-0.18/-0.2521.5M/20.91M+28%+2.82%Free Sign Up
09/2024-0.19/-0.2721.1M/19.07M+29.63%+10.64%Free Sign Up
06/2024-0.26/-0.319.3M/18.3M+13.33%+5.46%Free Sign Up
03/2024-0.32/-0.3218.1M/17.33M0%+4.44%Free Sign Up
12/2023-0.23/-0.3218.01M/17.41M+28.13%+3.45%Free Sign Up
09/2023-0.28/-0.416.4M/14.23M+30%+15.25%Free Sign Up

All numbers in USD

Neuropace Inc Earnings Call Summary for Q3/2025

  • NeuroPace exceeded Q3 2025 expectations with EPS of -$0.11 (vs -$0.20 forecast) and revenue of $27.4M (30% YoY growth), achieving positive adjusted EBITDA for the first time.
  • The company raised full-year revenue guidance to $97-98M (21-23% YoY growth) and increased gross margin guidance to 76-77%, despite stock remaining unchanged at $9.4 post-earnings.
  • NeuroPace is strategically focusing on its RNS business (revenue up 31% YoY to $22.6M) while winding down the Dixie product line, targeting PMA supplement submission for IGE indication by year-end.
  • Management projects gross margins of at least 80% for 2026 as the company transitions to a pure RNS business, positioning NeuroPace as 'the foundation of the future standard in individualized brain neuromodulation.'
Last Updated: 2025-11-04, 05:58 p/m
Read Full Transcript

FAQ

What Is Neuropace's Earnings Per Share (TTM)?

The Neuropace EPS (TTM) is -0.75.

When Is The Next Neuropace Earnings Date?

Neuropace will release its next earnings report on Mar 10, 2026.

What Is Neuropace’s Revenue Forecasts For Upcoming Quarters?

Neuropace’s revenue forecast is 22.02M.

How Did Neuropace React to the Company's Latest Earnings Report?

Neuropace reported a +45% EPS surprise and a +12.71% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 38.09%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.